International Journal of Medical Toxicology & Legal Medicine **Volume 27, No. 4, 2024**
e-ISSN: 0974-4614
p-ISSN: 0972-0448

Prevention and Management of Healthcare-Associated Infections: Focus on Pneumonia and UTI

Abdullah Mana Mohammed Alqahtani[1], Khalid Ali Zaher Alzahiri[2], Saleh Hassan Ali[3], Abdullah Hassan Abdullah Awaji Alsaluli[4], Naif Hamoud Dh Alotaibi[5], Salman Bakhet Almutairi[6], Ghzeha othman ALotieby[7], Laila Ali Musaad Al shehri[8], Saleh Ahmad S Alebaidi[9]

Internal Medicine[1], Pharmacy Technician[2,3,4],
ARMED FORCES HOSPITALS, SOUTHERN REGION
Nurse[5], Dawadmi Hospital
Pharmacy technician[6], Adderyah hospital, nursing[7], Health center Mohammedia, northern sector, pharmacist[8], Ministry of Health, Specialist-Laboratory[9] – Microbiology, Ministry of Health

bb0507738@gmail.com**,** alzahri90@gmail.com**,** saleh7assan@gmail.com**,** awaji2312@hotmail.com**,** nahalotaibi@moh.gov.sa**,** sabamo97@gmail.com**,** Ghzeha@moh.gov.sa, lalshehri@gov.moh.sa, saaalobaidi@moh.gov.sa

Received: 12.09.2024 Revised: 18.10.2024 Accepted: 15.11.2024

ABSTRACT
Patients admitted to an acute care hospital or living in a long-term care facility have an increased risk of HAIs which usually include a wide range of infections involving different organs or systems, such as those affecting the lower respiratory tract, urinary tract, and bloodstream/vascular system. Rehabilitation units serve a specific segment of society, and patients include those at the highest risk for healthcare-associated illness, particularly those with chronic underlying illnesses, addictions, homelessness, immunosuppression, malignant diseases, prolonged hospitalizations, long-term endotracheal and intravenous catheters, chronic wounds, open fractures, and antimicrobial resistance. High vigilance for HAIs must be maintained, with adherence to guidelines and surveillance measures for prevention and early detection, in strict collaboration with the public health system, especially when a threatened outbreak of an antimicrobial-resistant strain is concerned. When HAIs are suspected, early multidisciplinary approaches are required, even as a catalyst to direct infection control measures. However, cautious use of broad-spectrum antimicrobials, early empirical treatments, and early diagnostics, with few but comprehensive invasive procedures, should be performed. Non-antimicrobial preventive therapies could be implemented for specific patient populations, but future alternatives for disease prevention, such as vaccines, monoclonal antibodies, and new chemical entities, will be available to clinicians.

Keywords: Hospital acquired infections, Urinary tract infections, Hospital acquired pneumonia.

1. Introduction to Healthcare-Associated Infections

Healthcare-associated infections (HAIs) are infections a patient acquires while receiving care in a healthcare setting (1). These infections were not present at the time of admission but emerged 48 h or more after hospital admission or within 30 days of treatments (2).

Procedural or device-associated HAIs may arise following an invasive diagnostic or therapeutic procedure or the insertion of a device (3). They can occur in various locations where patients receive healthcare delivery. However, hospitals, particularly the intensive care unit (ICU) setting, can significantly increase the risk of acquiring Infection (4). Intensive care patients are vulnerable to infections due to chronic underlying diseases and the use of life-sustaining devices (5). The commonly observed HAIs in ICUs include ventilator-associated pneumonia (VAP), catheter-associated urinary tract infection (CAUTI), catheter-associated bloodstream infection (CABSI), and surgical site infection (SSI) (6).

HAIs increase morbidity, mortality, and length of hospital stay (LOS), leading to huge financial losses in the hospital sector from undisclosed expenditureand the need to clear the Infection (7). The public health implications are enormous as most of the bacterial pathogens causing HAIs are multidrug-resistant (8). Monitoring hospital environments is essential to prevent the transmission and spread of HAIs (9). Contracting an HAI puts patients at risk for serious complications and even death. It also places a burden on the healthcare system, taking up additional time and resources for monitoring and treatment (10). However, the good news is that HAIs can be prevented. Healthcare professionals play a crucial role in preventing HAIs. Therefore, it is essential to understand the issue, causes, and possible solutions (6). The following sections will discuss the epidemiology, pathophysiology, prevention, and management of pneumonia and UTI, the two most common HAIs.

2. Epidemiology of Pneumonia and UTI in Healthcare Settings

To effectively reduce healthcare-associated pneumonia and urinary tract infections (UTI), an understanding of their prevalence and epidemiology in healthcare settings is crucial (11). Pneumonia accounts for 36-46% of all infection-related deaths in healthcare environments. ICU patients are at a 6-21 times higher risk for acquiring pneumonia, with one-third of these pneumonias being associated with mechanical ventilation (12). Despite improvements in preventive measures, the incidence of pneumonia remains significant in ICU patients (13). General ward patients also acquire pneumonia, albeit through different mechanisms than those in the ICU (14). Epidemiological data is vital for addressing HAIs as it helps identify patient groups at increased risk and focus prevention efforts where most needed (15). Similarly, UTIs are the most common HAIs, with an annual incidence of approximately 3 million (16). Critically ill patients, particularly in ICUs, are at a 4-30 times greater risk for developing healthcare-associated UTI (17). These infections account for 31-36% of all HAIs and 1-25% of infection-related deaths (18).

While UTIs acquired in ICUs differ in pathogenesis from those in general wards, the latter still account for significant morbidity and mortality (19). Understanding the epidemiology of pneumonia and UTI is essential for planning effective preventive measures. Infection rates are influenced by various factors, including age, gender, and length of stay in healthcare facilities (20). Since the majority of these infections are associated with antibiotic-resistant pathogens, understanding antibiotic resistance patterns is crucial (21). Identifying patient groups at highest risk is necessary for planning specific intervention strategies. The epidemiology of pneumonia and UTI in healthcare settings is reviewed to provide a basis for discussing risk factors, preventive measures, and management (22).

3. Pathophysiology and Risk Factors

HAIs are a significant challenge in today's healthcare system. Growing antibiotic resistance poses a threat to already vulnerable populations, leading to increased morbidity and mortality (23). Pneumonia and UTIs account for nearly one-third of all HAIs, affecting patients already weakened by comorbidities (22). Understanding the mechanisms of these infections can increase awareness and possibilities for initiation of preemptive strategies (24). Infection development is complex, as pathogens can invade, survive, and multiply in hostile environments while evading the immune system (25). Consideration of the pathogen's point of view can illustrate successful infection establishment (26). Each selected pathogen has characteristics that promote infection. Risk factors for pneumonias and UTIs are examined in detail (27).

Most common risk factors are age, various comorbidities, and immunosuppression due to underlying diseases or treatments (28). Elements in the environment, such as catheter use or prolonged mechanical ventilation, also contribute significantly (29). One pathogen can exploit several pathways and host weaknesses, and infection establishment often depends on multiple factors working together (30). A pathogen actively inducing a disease persists in the infected tissue, usually at the expense of the host's fitness. Pathogens have evolved elaborate mechanisms to invade, survive, and multiply in host tissues while evading the immune response (31).

Understanding both pathogen and host responses is essential for describing the infection mechanisms in detail (32). Inflammation is the first stage of the immune response that attempts to repair damaged tissue and eliminate invading pathogens. It is characterized by increased blood flow to the affected site, increased permeability of local blood vessels, and the recruitment of various immune cells to the tissue (33). Pathogen invasion often triggers inflammation. Depending on the pathogen type, this can be recognized either directly by immune receptors or indirectly through damaged host cells (34). A complex network of cytokines and chemokines is activated to attract various immune cells to the infection site (35). Pathogen transmission often occurs directly, such as through contact with infected secretions, or indirectly

through contaminated surfaces (36). Most infections begin at mucosal surfaces, constituting a significant part of the body and acting as a barrier to the environment (37).

Mucosal surfaces are continuously bathed in secretions containing antimicrobial factors, such as mucins impeding pathogen adhesion, lysozyme disrupting bacterial cell walls, secretory IgA neutralizing pathogens, and lactoferrin sequestering iron essential for pathogen growth (38, 39). In addition to the innate immune system, the mucosal surfaces harbor a significant portion of the body's adaptive immune system. Mucosal antigen sampling induces local immune responses and the generation of memory lymphocytes, which can also mount systemic responses (40). Despite these defenses, mucosal infections are common. Most respiratory pathogen infections initially target epithelial cells, and successful infections usually induce minimal pathogenicity (41).

The host normally clears the infection, often without detectable inflammation or systemic spread of the pathogen (42). Available evidence indicates that invading respiratory pathogens exploit host mechanisms to gain entry and restrict pathogen spread (43). Pathogen-induced alterations in host cell signaling pathways can enhance adherence and invasion while dampening pro-inflammatory cytokine production (44). In contrast, successful establishment of most systemic infections requires the pathogen to breach and invade the epithelium (45). This commonly results in tissue damage and local inflammation, though the pathways exploited to induce tissue invasion are often similar to those used in mucosal infections (45).

4. Preventive Strategies for Pneumonia and UTI

Pneumonia and urinary tract infections (UTI) are common HAIs that cause significant morbidity and mortality in healthcare settings (22). Pneumonia is usually the result of an infection acquired during hospitalization, with VAP occurring in critically ill patients on mechanical ventilation (46). UTIs are the most common HAIs, primarily due to the use of indwelling urinary catheters. This article aims to summarize the best preventive measures to significantly reduce the incidence of pneumonia and UTI in healthcare settings (47). The focus is on the most current, relevant, and evidence-based strategies for prevention supported by the latest guidelines (48).

Single prevention strategies alone are often insufficient to reduce pneumonia and UTI rates significantly (9, 16). Instead, a combination of approaches should be used for the best results. Simple measures, such as ensuring proper hand hygiene or raising the head of the bed, can reduce the incidence of pneumonia (49). More complex strategies, such as active and intensivist-led management protocols for sedation and neuromuscular blocking agents, are needed to prevent pneumonia in patients with a high risk of VAP (50).

Similarly, for UTI, basic strategies focusing on the proper insertion technique and maintenance of urinary catheters can be implemented (51). More comprehensive strategies require a multi-disciplinary team to review the appropriateness of urinary catheters and other preventive measures at regular intervals (52). These strategies can achieve significant reductions in the incidence of HAIs, sometimes by more than 50% (53). However, achieving and maintaining compliance with some preventive measures, especially complex strategies for HAIs , can be difficult. Nonetheless, the message is clear: pneumonia and UTIs can and should be prevented, and the best approach is systematic, multi-faceted, and proactive vigilance (54).

5. Management and Treatment Approaches

Preventative strategies are critically important in limiting the spread of HAIs, and they necessitate thorough planning of ideal patient management pathways in close collaboration with Infection Prevention and Control (IPC) teams (6, 16, 22). However, it ultimately falls upon the clinical staff to ensure that these planned pathways are adequately enacted and followed through. Consequently, careful consideration is given to the clinical management of HAI specifically in patients, with particular emphasis placed on pneumonia and UTI (55).

Effectively treating pneumonia and UTI within healthcare settings demands a comprehensive, multi-faceted approach (56). Among key therapeutic strategies, the utilization of antibiotics takes precedence, with the appropriate selection of these medications being guided primarily by culture and sensitivity results (57). However, challenges such as the evolving landscape of antibiotic resistance necessitate that alternative treatment modalities are carefully considered and judiciously implemented (58). Prompt clinical intervention is absolutely critical in managing HAIs infections, where a strong emphasis is placed on the ongoing monitoring of patients for potential treatment failures (59).

The significance of prompt clinical intervention is immense, as it has the potential to greatly affect and enhance the results for patients. Additionally, interdisciplinary teams are crucial in addressing infections stemming from various diseases (60). Specialists in infectious diseases play a vital role in

ensuring that patient care is delivered consistently and effectively across all care levels. It is also crucial for thorough discussions to occur with patients and their families concerning follow-up care, rehabilitation, and recovery after an infection (61).

These discussions should address the holistic needs of the individual during their healing journey. Management plans must not be static; they should be regularly assessed and thoughtfully adjusted based on new evidence and each patient's response to treatment strategies. A collaborative approach among various disciplines involved in patient care is essential, ensuring integration throughout the management process.

Prespectives and future directions

The diversity of challenges and opportunities related to hospital care, prevention, and management of infections and antimicrobial stewardship was reflected in the presentations and discussions of the Deans of Infection Control Symposium (62). Topics addressed encompassed epidemiology of infectious diseases, prevention, and control of hospital-acquired infections, infection control recommendations, and issues specific to healthcare institutions, identification of the most common microorganisms and their resistance phenotypes, new technologies for rapid diagnosis and susceptibility testing, new drug development, treatment guidelines, and novel therapies (63). Universal access to antimicrobials and multistrategies for individual therapy choices have been recognized as major challenges for developing the control of infections (64).

Consequently, in the current era, rapid technological advancements reshape infection management (65). The awareness of such developments is a critical aspect of modern medical practice, and their impact on both the predisposing host conditions as well as the related microbiological questions, such as genomic sequencing opening new roads in microbiology, typically allowing identification and person-based guidance within hours and antibiotic sensitivity in a few days (66, 67). These are needed more than ever, taking into account that the quality and timeliness of care are still necessities in the healthcare system 68. The timely diagnosis and appropriate empiric therapy are fundamental for optimized infection management and essential for patient care as well as comprehensive stewardship to maintain antibiotic effectiveness for the next generations (69).

CONCLUSION

Infections acquired during the provision of healthcare are a major cause of morbidity and mortality. They also contribute to increases in the costs of care. From an economic perspective, many of these infections are preventable. This is particularly true of those associated with the provision of critical care. Not only can a patient suffer the consequences of a healthcare-acquired infection, but the presence of these infections may also bring about isolation, anxiety and depression, with a consequent impairment of rehabilitation. Good knowledge of the factors responsible for the development of these infections combined with good preventive measures and the correct management of the infection when it is diagnosed should permit a great reduction in the level of morbidity and mortality resulting from these serious problems.

REFERENCES:

1. Mazzeffi M, Galvagno S, Rock C. Prevention of healthcare-associated infections in intensive care unit patients. Anesthesiology. 2021 Nov 9;135(6):1122-31.
2. Alrebish SA, Yusufoglu HS, Alotibi RF, Abdulkhalik NS, Ahmed NJ, Khan AH. Epidemiology of healthcare-associated infections and adherence to the HAI prevention strategies. InHealthcare 2022 Dec 26 (Vol. 11, No. 1, p. 63).
3. Dadi NC, Radochová B, Vargová J, Bujdáková H. Impact of healthcare-associated infections connected to medical devices—An update. Microorganisms. 2021 Nov 11;9(11):2332.
4. Mazzeffi M, Galvagno S, Rock C. Prevention of healthcare-associated infections in intensive care unit patients. Anesthesiology. 2021 Nov 9;135(6):1122-31.
5. NWOZICHI CU, OLORUNFEMI O. Intensive care environment: Perspective of relatives of critically ill patient sustained by health technology. Journal of Integrative Nursing. 2023 Apr 1;5(2):102-7.
6. Blot S, Ruppé E, Harbarth S, Asehnoune K, Poulakou G, Luyt CE, Rello J, Klompas M, Depuydt P, Eckmann C, Martin-Loeches I. Healthcare-associated infections in adult intensive care unit patients: Changes in epidemiology, diagnosis, prevention and contributions of new technologies. Intensive and Critical Care Nursing. 2022 Jun 1;70:103227.
7. Nunes S. *Predicting Length of Stay (LOS) in a Hospital Post-Sugery* (Master's thesis, Universidade NOVA de Lisboa (Portugal)).

8. Salmanov A, Shchehlov D, Svyrydiuk O, Bortnik I, Mamonova M, Korniyenko S, Rud V, Artyomenko V, Gudym M, Maliarchuk R, Bondar T. Epidemiology of healthcare-associated infections and mechanisms of antimicrobial resistance of responsible pathogens in Ukraine: a multicentre study. Journal of Hospital Infection. 2023 Jan 1;131:129-38.
9. Sartelli M, Marini CP, McNelis J, Coccolini F, Rizzo C, Labricciosa FM, Petrone P. Preventing and Controlling Healthcare-Associated Infections: The First Principle of Every Antimicrobial Stewardship Program in Hospital Settings. Antibiotics. 2024 Sep 20;13(9):896.
10. Singh HK, Claeys KC, Advani SD, Ballam YJ, Penney J, Schutte KM, Baliga C, Milstone AM, Hayden MK, Morgan DJ, Diekema DJ. Diagnostic stewardship to improve patient outcomes and healthcare-associated infection (HAI) metrics. Infection Control & Hospital Epidemiology. 2024 Apr;45(4):405-11.
11. Tesini BL, Dumyati G. Health care-associated infections in older adults: epidemiology and prevention. Infectious Disease Clinics. 2023 Mar 1;37(1):65-86.
12. Anderson R, Feldman C. The global burden of community-acquired pneumonia in adults, encompassing invasive pneumococcal disease and the prevalence of its associated cardiovascular events, with a focus on pneumolysin and macrolide antibiotics in pathogenesis and therapy. International Journal of Molecular Sciences. 2023 Jul 3;24(13):11038.
13. Nair GB, Niederman MS. Updates on community acquired pneumonia management in the ICU. Pharmacology & therapeutics. 2021 Jan 1;217:107663.
14. Pereverzeva L, Uhel F, Peters Sengers H, Cremer OL, Schultz MJ, Bonten MM, Scicluna BP, van der Poll T, MARS consortium t. vanderpoll@ amsterdamumc. nl. Association between delay in intensive care unit admission and the host response in patients with community-acquired pneumonia. Annals of intensive care. 2021 Dec;11:1-3.
15. Datta P, Rani H, Chauhan R, Gombar S, Chander J. Health-care-associated infections: Risk factors and epidemiology from an intensive care unit in Northern India. Indian journal of anaesthesia. 2014 Jan 1;58(1):30-5.
16. Werneburg GT. Catheter-associated urinary tract infections: current challenges and future prospects. Research and reports in urology. 2022 Apr 4:109-33.
17. Shrestha SK, Trotter A, Shrestha PK. Epidemiology and risk factors of Healthcare-Associated infections in critically ill patients in a Tertiary Care Teaching Hospital in Nepal: a prospective cohort study. Infectious Diseases: Research and Treatment. 2022 Jan;15:11786337211071120.
18. van der Jagt EW, Short SR. Healthcare-Associated Infections. Pediatric Critical Care: Text and Study Guide. 2021:1105-43.
19. Ginter K, Schwab F, Behnke M, Wolkewitz M, Gastmeier P, Geffers C, Maechler F. SAPS2, APACHE2, SOFA, and Core-10-TISS upon admission as risk indicators for ICU-acquired infections: a retrospective cohort study. Infection. 2023 Aug;51(4):993-1001.
20. Nelson RE, Hyun D, Jezek A, Samore MH. Mortality, length of stay, and healthcare costs associated with multidrug-resistant bacterial infections among elderly hospitalized patients in the United States. Clinical Infectious Diseases. 2022 Mar 15;74(6):1070-80.
21. Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2021 Oct 12;10(10):1310.
22. Cristina ML, Spagnolo AM, Giribone L, Demartini A, Sartini M. Epidemiology and prevention of healthcare-associated infections in geriatric patients: a narrative review. International Journal of Environmental Research and Public Health. 2021 May 17;18(10):5333.
23. Elbehiry A, Marzouk E, Abalkhail A, El-Garawany Y, Anagreyyah S, Alnafea Y, Almuzaini AM, Alwarhi W, Rawway M, Draz A. The development of technology to prevent, diagnose, and manage antimicrobial resistance in healthcare-associated infections. Vaccines. 2022 Dec 8;10(12):2100.
24. Choi MY, Costenbader KH. Understanding the concept of pre-clinical autoimmunity: prediction and prevention of systemic lupus erythematosus: identifying risk factors and developing strategies against disease development. Frontiers in immunology. 2022 Jun 3;13:890522.
25. Milgroom MG. Biology of Infectious Disease: From Molecules to Ecosystems. Springer Nature; 2023 Nov 25.
26. Fagre AC, Cohen LE, Eskew EA, Farrell M, Glennon E, Joseph MB, Frank HK, Ryan SJ, Carlson CJ, Albery GF. Assessing the risk of human-to-wildlife pathogen transmission for conservation and public health. Ecology Letters. 2022 Jun;25(6):1534-49.

27. Timm MR, Russell SK, Hultgren SJ. Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics. Nature Reviews Microbiology. 2024 Sep 9:1-5.
28. Salminen A. Clinical perspectives on the age-related increase of immunosuppressive activity. Journal of Molecular Medicine. 2022 May;100(5):697-712.
29. Hill B, Lamichhane G, Wamburu A. Infection prevention and control: critical strategies for nursing practice. British Journal of Nursing. 2024 Sep 19;33(17):804-11.
30. Dutt A, Andrivon D, Le May C. Multi-infections, competitive interactions, and pathogen coexistence. Plant Pathology. 2022 Jan;71(1):5-22.
31. Murdoch CC, Skaar EP. Nutritional immunity: the battle for nutrient metals at the host–pathogen interface. Nature Reviews Microbiology. 2022 Nov;20(11):657-70.
32. Ellner SP, Buchon N, Dörr T, Lazzaro BP. Host–pathogen immune feedbacks can explain widely divergent outcomes from similar infections. Proceedings of the Royal Society B. 2021 May 26;288(1951):20210786.
33. Galea I. The blood–brain barrier in systemic infection and inflammation. Cellular & molecular immunology. 2021 Nov;18(11):2489-501.
34. Paludan SR, Pradeu T, Masters SL, Mogensen TH. Constitutive immune mechanisms: mediators of host defence and immune regulation. Nature Reviews Immunology. 2021 Mar;21(3):137-50.
35. Harvanová G, Duranková S, Bernasovská J. The role of cytokines and chemokines in the inflammatory response. Alergologia Polska-Polish Journal of Allergology. 2023;10(3):210-9.
36. Li Y. Basic routes of transmission of respiratory pathogens—A new proposal for transmission categorization based on respiratory spray, inhalation, and touch. Indoor Air. 2021 Jan;31(1):3.
37. Bustos NA, Ribbeck K, Wagner CE. The role of mucosal barriers in disease progression and transmission. Advanced Drug Delivery Reviews. 2023 Sep 1;200:115008.
38. Şenel S. An overview of physical, microbiological and immune barriers of oral mucosa. International journal of molecular sciences. 2021 Jul 22;22(15):7821.
39. Johnstone KF, Herzberg MC. Antimicrobial peptides: Defending the mucosal epithelial barrier. Frontiers in Oral Health. 2022 Aug 1;3:958480.
40. Suárez LJ, Arboleda S, Angelov N, Arce RM. Oral versus gastrointestinal mucosal immune niches in homeostasis and allostasis. Frontiers in Immunology. 2021 Jul 5;12:705206.
41. Hewitt RJ, Lloyd CM. Regulation of immune responses by the airway epithelial cell landscape. Nature Reviews Immunology. 2021 Jun;21(6):347-62.
42. Medzhitov R. The spectrum of inflammatory responses. Science. 2021 Nov 26;374(6571):1070-5.
43. Barron SL, Saez J, Owens RM. In vitro models for studying respiratory host–pathogen interactions. Advanced Biology. 2021 Jun;5(6):2000624.44.
44. Pei G, Dorhoi A. NOD-like receptors: Guards of cellular homeostasis perturbation during infection. International journal of molecular sciences. 2021 Jun 23;22(13):6714.
45. Rogers AP, Mileto SJ, Lyras D. Impact of enteric bacterial infections at and beyond the epithelial barrier. Nature Reviews Microbiology. 2023 Apr;21(4):260-74.
46. Giacobbe DR, Battaglini D, Enrile EM, Dentone C, Vena A, Robba C, Ball L, Bartoletti M, Coloretti I, Di Bella S, Di Biagio A. Incidence and prognosis of ventilator-associated pneumonia in critically ill patients with COVID-19: a multicenter study. Journal of clinical medicine. 2021 Feb 3;10(4):555.
47. Medina-Polo J, Naber KG, Johansen TE. Healthcare-associated urinary tract infections in urology. GMS infectious diseases. 2021;9.
48. Mehta Y, Gupta A, Todi S, Myatra SN, Samaddar DP, Patil V, Bhattacharya PK, Ramasubban S. Guidelines for prevention of hospital acquired infections. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine. 2014 Mar;18(3):149.
49. Lakra S. Ventilator associated pneumonia and nurses role in prevention: A scoping review. 2022.
50. ARRESTS C, SALINE H. SOCIETY OF CRITICAL CARE MEDICINE 52ND CRITICAL CARE CONGRESS.
51. Gad MH, AbdelAziz HH. Catheter-associated urinary tract infections in the adult patient group: a qualitative systematic review on the adopted preventative and interventional protocols from the literature. Cureus. 2021 Jul;13(7).

52. Na SH, Eom JS, Seo YB, Park SH, Kim YK, Song W, Lee E, Kim SR, Yoo HM, Chun H, Shin MJ. Impact of Infection Prevention Programs on Catheter-Associated Urinary Tract Infections Analyzed in Multicenter Study. Journal of Korean Medical Science. 2024 May 5;39(18).
53. Peters A, Schmid MN, Parneix P, Lebowitz D, de Kraker M, Sauser J, Zingg W, Pittet D. Impact of environmental hygiene interventions on healthcare-associated infections and patient colonization: a systematic review. Antimicrobial Resistance & Infection Control. 2022 Feb 19;11(1):38.
54. Gupta A, Petty L, Gandhi T, Flanders S, Hsaiky L, Basu T, Zhang Q, Horowitz J, Masood Z, Chopra V, Vaughn VM. Overdiagnosis of urinary tract infection linked to overdiagnosis of pneumonia: a multihospital cohort study. BMJ quality & safety. 2022 May 1;31(5):383-6.
55. Nagaraj C. Hospital-Acquired Urinary Tract Infections. InAdvances and Challenges in Urine Laboratory Analysis 2023 Apr 12. IntechOpen.
56. Yue C, Cui Z, Yang G, He X, Wang L, Xin Z, Tang L. Effect of unifaceted and multifaceted interventions on antibiotic prescription control for respiratory diseases: a systematic review of randomized controlled trials.
57. Uddin TM, Chakraborty AJ, Khusro A, Zidan BR, Mitra S, Emran TB, Dhama K, Ripon MK, Gajdács M, Sahibzada MU, Hossain MJ. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. Journal of infection and public health. 2021 Dec 1;14(12):1750-66.
58. Saeed U, Insaf RA, Piracha ZZ, Tariq MN, Sohail A, Abbasi UA, Fida Rana MS, Gilani SS, Noor S, Noor E, Waheed Y. Crisis averted: a world united against the menace of multiple drug-resistant superbugs-pioneering anti-AMR vaccines, RNA interference, nanomedicine, CRISPR-based antimicrobials, bacteriophage therapies, and clinical artificial intelligence strategies to safeguard global antimicrobial arsenal. Frontiers in Microbiology. 2023 Nov 30;14:1270018.
59. Meddings J, Saint S, Chopra V. Preventing hospital infections: real-world problems, realistic solutions. Oxford University Press; 2021.
60. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023 Dec 1;102(48):e36462.
61. Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Primary care guidance for persons with human immunodeficiency virus: 2020 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical infectious diseases. 2021 Dec 1;73(11):e3572-605.
62. van Rooden SM, van der Werff SD, van Mourik MS, Lomholt F, Møller KL, Valk S, dos Santos Ribeiro C, Wong A, Haitjema S, Behnke M, Rinaldi E. Federated systems for automated infection surveillance: a perspective. Antimicrobial Resistance & Infection Control. 2024 Sep 27;13(1):113.
63. Florensa AF, Kaas RS, Clausen PT, Aytan-Aktug D, Aarestrup FM. ResFinder–an open online resource for identification of antimicrobial resistance genes in next-generation sequencing data and prediction of phenotypes from genotypes. Microbial Genomics. 2022 Jan 24;8(1):000748.
64. Huang Y, Lin X, Yu S, Chen R, Chen W. Intestinal engineered probiotics as living therapeutics: chassis selection, colonization enhancement, gene circuit design, and biocontainment. ACS synthetic biology. 2022 Sep 12;11(10):3134-53.
65. George AS, George AH. Riding the wave: an exploration of emerging technologies reshaping modern industry. Partners Universal International Innovation Journal. 2024 Feb 25;2(1):15-38.
66. Serpa PH, Deng X, Abdelghany M, Crawford E, Malcolm K, Caldera S, Fung M, McGeever A, Kalantar KL, Lyden A, Ghale R. Metagenomic prediction of antimicrobial resistance in critically ill patients with lower respiratory tract infections. Genome medicine. 2022 Jul 12;14(1):74.
67. Sauerborn E, Corredor NC, Reska T, Perlas A, Vargas da Fonseca Atum S, Goldman N, Wantia N, Prazeres da Costa C, Foster-Nyarko E, Urban L. Detection of hidden antibiotic resistance through real-time genomics. Nature Communications. 2024 Jun 28;15(1):5494.
68. Hannawa AF, Wu AW, Kolyada A, Potemkina A, Donaldson LJ. The aspects of healthcare quality that are important to health professionals and patients: A qualitative study. Patient education and counseling. 2022 Jun 1;105(6):1561-70.
69. Zacharioudakis IM, Zervou FN. Diagnostic stewardship in infectious diseases: steps towards intentional diagnostic testing. Future Microbiology. 2022 Jul;17(11):813-7.